Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios.
Pizzuti L, Krasniqi E, Barchiesi G, Mazzotta M, Barba M, Amodio A, Massimiani G, Pelle F, Kayal R, Vizza E, Grassadonia A, Tomao S, Venuti A, Gamucci T, Marchetti P, Natoli C, Sanguineti G, Ciliberto G, Vici P. Pizzuti L, et al. Among authors: tomao s. J Cancer. 2019 Oct 12;10(24):5903-5914. doi: 10.7150/jca.35109. eCollection 2019. J Cancer. 2019. PMID: 31762800 Free PMC article. Review.
Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G, Capalbo C, Ristori E, Ricevuto E, Sidoni T, Buffone A, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A. Giannini G, et al. Among authors: tomao s. Breast Cancer Res Treat. 2006 Nov;100(1):83-91. doi: 10.1007/s10549-006-9225-9. Epub 2006 May 9. Breast Cancer Res Treat. 2006. PMID: 16847550
Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families.
Buffone A, Capalbo C, Ricevuto E, Sidoni T, Ottini L, Falchetti M, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G. Buffone A, et al. Among authors: tomao s. Breast Cancer Res Treat. 2007 Dec;106(2):289-96. doi: 10.1007/s10549-007-9499-6. Epub 2007 Feb 28. Breast Cancer Res Treat. 2007. PMID: 17333342
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Fabi A, Metro G, Papaldo P, Mottolese M, Melucci E, Carlini P, Sperduti I, Russillo M, Gelibter A, Ferretti G, Tomao S, Milella M, Cognetti F. Fabi A, et al. Among authors: tomao s. Cancer Chemother Pharmacol. 2008 Sep;62(4):717-25. doi: 10.1007/s00280-007-0650-1. Epub 2007 Dec 6. Cancer Chemother Pharmacol. 2008. PMID: 18071704 Clinical Trial.
Breast cancer risk after exposure to fertility drugs.
Lo Russo G, Spinelli GP, Tomao S, Rossi B, Frati L, Panici PB, Vici P, Codacci Pisanelli G, Tomao F. Lo Russo G, et al. Among authors: tomao s, tomao f. Expert Rev Anticancer Ther. 2013 Feb;13(2):149-57. doi: 10.1586/era.12.181. Expert Rev Anticancer Ther. 2013. PMID: 23406556 Review.
Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff?
Gazzaniga P, Raimondi C, Gradilone A, Biondi Zoccai G, Nicolazzo C, Gandini O, Longo F, Tomao S, Lo Russo G, Seminara P, Vincenzi B, Chimenti I, Cristofanilli M, Frati L, Cortesi E. Gazzaniga P, et al. Among authors: tomao s. J Cancer Res Clin Oncol. 2013 Aug;139(8):1411-6. doi: 10.1007/s00432-013-1450-0. Epub 2013 Jun 5. J Cancer Res Clin Oncol. 2013. PMID: 23736274
209 results